Search for: "Ariad Pharmaceuticals Inc."
Results 21 - 40
of 103
Sort by Relevance
|
Sort by Date
29 Oct 2013, 9:55 am
See, e.g., Ariad Pharmaceuticals, Inc. v. [read post]
28 May 2013, 10:51 am
From Ex parte GillisAs to written description:“[T]he written description requirement does not demand eitherexamples or an actual reduction to practice; a constructive reduction topractice that in a definite way identifies the claimed invention can satisfy thewritten description requirement” Ariad Pharmaceuticals, Inc. v. [read post]
1 Apr 2013, 9:11 pm
Cir. 1996) Ariad Pharmaceuticals, Inc. v. [read post]
24 Oct 2011, 9:36 am
[4] Ariad Pharmaceuticals, Inc. v. [read post]
22 Aug 2011, 2:00 am
See Ariad Pharmaceuticals, Inc. v. [read post]
22 Aug 2011, 2:00 am
See Ariad Pharmaceuticals, Inc. v. [read post]
1 Apr 2011, 5:17 pm
In Ariad Pharmaceuticals, Inc. [read post]
1 Apr 2011, 12:42 pm
In Ariad Pharmaceuticals, Inc. v. [read post]
10 Mar 2011, 5:00 am
” The complaint focuses on two public companies for which Silverman received non-public information through Guidepoint consultants: Ariad Pharmaceuticals, Inc. and Questcor Pharmaceuticals Inc. [read post]
10 Mar 2011, 5:00 am
The complaint focuses on two public companies for which Silverman received non-public information through Guidepoint consultants: Ariad Pharmaceuticals, Inc. and Questcor Pharmaceuticals Inc. [read post]
8 Mar 2011, 1:23 pm
Cir. 2010) (en banc) Ariad Pharmaceuticals, Inc. v. [read post]
31 Jan 2011, 8:10 am
Kappos, to Ariad Pharmaceuticals v. [read post]
31 Jan 2011, 8:10 am
Kappos, to Ariad Pharmaceuticals v. [read post]
4 Sep 2010, 8:29 pm
" Ariad Pharms., Inc. v. [read post]
1 Sep 2010, 4:46 pm
Eon Labs, Inc. and Elan Pharmaceuticals, Inc. at http://www.patentlyo.com/patent/2010/08/ignoring-non-patentable-elements-while-judging-novelty.html Hyatt v. [read post]
4 Jun 2010, 3:36 pm
In Ariad Pharmaceuticals, Inc. v. [read post]
21 May 2010, 8:58 am
See Not Losing the Forest for the Trees: Newman Concurs in Ariad where Newman’s concurring opinion concisely captured the essence (and not simply the form) of the “written description” requirement, and why the patent in Ariad Pharmaceuticals v. [read post]
19 May 2010, 6:15 am
Lupin Pharmaceuticals, Inc. [read post]
13 May 2010, 4:58 pm
Watson Pharmaceuticals Inc. et al. [read post]
5 May 2010, 2:03 pm
On March 22, 2010, the Federal Circuit issued an en banc decision in Ariad Pharmaceuticals, Inc v. [read post]
